CClinicalTrials.gg
CompletedNCT03796091Updated Dec 9, 2022Results posted

Efficacy Trial of a Dissonance Based Eating Disorder Program

An interventional study of Educational Brochure and Body Project Traditional in Eating Disorder, sponsored by Cornell College. Completed at 1 site in United States. Open to female participants aged 15 Years to 34 Years. Per ClinicalTrials.gov, last updated 2022-12-09.

Sponsored by Cornell College · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
15 Years to 34 Years
Sex
Female
01

Study summary

The purpose of this clinical trial is to investigate whether symptoms of disordered eating change among participants who complete an intervention. Participants will be randomly assigned to one of three intervention conditions and will undergo assessments of symptoms before, after, and 2 months after each intervention. Investigators are evaluating which interventions are most effective in reducing eating disorder symptoms and disorder-related psychological and cardiac risk factors.

Read the detailed description

Assessment Sessions (Preintervention, Postintervention, 2-month follow-up): Participants in all conditions will participate in a series of 3 assessment sessions. Prior to each session, participants will complete online questions assessing eating disorder symptoms and associated psychological risk factors. This process will take approximately 40 minutes. Next participants will report to the laboratory at their scheduled appointment time to have their cardiac function assessed via blood pressure measurements and electrocardiography (EKG or ECG). Participants' height and weight will also be recorded.

Prior to each assessment session, participants should:

  • Complete the online survey (if not completed prior to each laboratory appointment this will need to be completed at the lab appointment)
  • Fast (not consume any food or beverages other than water) for at least 3 hours.
  • Refrain from using nicotine for at least 3 hours.
  • Refrain from vigorous physical exercise for at least 24 hours.
  • Not show any symptoms of acute physical illness for 48 hours. It is important for participants to follow these directions so researchers can gather the most accurate data. If participants forget to follow these guidelines, or if an illness occurs, participants should contact their experimenter to reschedule.

On the day of an assessment session, participants will drive to the assessment location. Participants will receive directions via e-mail prior to each session. During the assessment session, participants will lie down on a laboratory cot for 10 minutes while preparation for electrocardiography (EKG or ECG) occurs. Electrodes will be applied to the chest and torso and lead wires will be attached to the electrodes. Participants' blood pressure will be assessed several times throughout this interval. Next, the experimenter will collect a 5 minute and 30 second recording of participants' cardiovascular data via electrocardiography (ECG or EKG). This data will later be analyzed to examine cardiac function.Next experimenters will assess participants' height and weight.

After each assessment session, participants' eating disorder symptoms, psychological risk factors, and cardiac indices will be evaluated by the research team. If the team determines that symptoms or cardiac indices are atypical and indicate a further need for evaluation, the participant will be contacted via both e-mail and phone to be informed results are atypical and the participant will be referred for further evaluation by a medical provider. If the participant is a minor, this information will be provided both to the participant and to the participant's parent and/or the participant's legal guardian. If participants' symptoms or risk factors worsen significantly over the duration of the trial, participants will also be contacted and provided with referral recommendations.

All participants will receive a comprehensive symptom report at the end of the trial. Referral resources will be provided again at that time if significant eating disorder symptoms remain.

Treatment Conditions: Participants will be randomly assigned to 1 of 3 treatment conditions.

Brochure Treatment Condition: Participants randomly assigned to the educational brochure will receive two educational brochures which discuss eating disorder symptoms. The brochures will also include treatment referral information and recommended resources for persons struggling with disordered eating. The brochure will take approximately 10 minutes to read; follow-up with treatment or self-help referral resources is completely voluntary.

Group Therapy Treatment Conditions: Participants randomly assigned to one of the two group treatment intervention conditions will complete a 4-week group treatment program with 3-8 other women and 2 trained treatment co-facilitators. For approximately 1 hour each week, participants will meet in this group to complete a series of readings, written activities, and verbal activities designed to reduce disordered eating. During the 4 intervention sessions, participants will be asked to analyze the weight and appearance-related messages received from the media, peers, family, romantic partners, and other sources. Participants will also be asked to record, analyze, and evaluate weight and appearance-related thoughts, emotions, and behaviors. Participants will engage in a variety of exercises designed to evaluate the meaning of thinness in our culture and its personal impact. These exercises are designed to combat the detrimental impact of messages which promote thinness.

Other risk factors will also be addressed, depending upon program. Participants may talk about the pressures women receive to focus on appearance. The relationship between these appearance-related pressures and eating disorder symptoms will be explored. Participants will explore the way they compare themselves to others and participate in a series of discussions and activities designed to decrease appearance-based comparisons with others.

After the 4-week program is complete, participants in both intervention conditions will continue to work on homework assignments related to the program for a period of 2-months until the final assessment session.

02

Conditions studied

  • Eating Disorder
03

In context

Feeding and Eating Disorders

740 studies on the registry are indexed under Feeding and Eating Disorders; 159 are open to participants now.

This study's enrollment of 180 is above the median of 75 across 540 interventional studies indexed under Feeding and Eating Disorders.

Browse Feeding and Eating Disorders studies →

Lead sponsor

This is the only study on the registry with Cornell College as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 34 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Inclusion Criteria

    • Women
    • Age 15-34
    • Postmenarcheal
    • Premenopausal
    • Subclinical or Clinical Eating Disorder Symptoms

Exclusion Criteria:

  • Exclusion Criteria

    • Must get physician clearance to participate if at medically high risk as defined in the protocol
    • Must not be pregnant
    • Must be able to read and speak English
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (actual)

Study arms

  • Active comparator
    Educational Brochure

    Participants will read an educational brochure from the National Eating Disorder Association and will receive referral resources.

    Behavioral: Educational Brochure

  • Active comparator
    Body Project Traditional

    Participants will complete group therapy for 1-hour per week for 4 weeks consisting of the Body Project group therapy program (Stice \& Shaw, 2001).

    Behavioral: Body Project Traditional

  • Active comparator
    Body Project Expanded

    Participants will complete group therapy for 1-hour per week for 4 weeks consisting of the Body Project Expanded group therapy program (Green et al., 2017).

    Behavioral: Body Project Expanded

Interventions

  • BehavioralEducational Brochure

    Participants will read an educational brochure from the National Eating Disorders Association and will receive treatment referral resources.

  • BehavioralBody Project Traditional

    Participants will complete a 1-hour per week group therapy program for 4 weeks consisting of the Body Project Traditional group therapy program (see Stice \& Shaw, 2001).

  • BehavioralBody Project Expanded

    Participants will complete a 1-hour per week group therapy program for 4 weeks consisting of the Body Project Expanded group therapy program (see Green et al., 2017).

06

What researchers measure

Primary outcomes

  1. Rosenberg Self-Esteem Scale (RSE).

    The Rosenberg Self-Esteem Scale is designed to assess global feelings of self-worth. The RSE includes 10 items (e.g. "I feel that I'm a person of worth'') rated on a four-point scale (1 = strongly disagree, 4 = strongly agree). A total score represents the sum of individual item responses. Scores range from 10 to 40 and higher scores indicate higher levels of self-esteem.

    Time frame: Baseline assessments occurred after screening and prior to the delivery of any interventions.

  2. Rosenberg Self-Esteem Scale (RSE).

    The Rosenberg Self-Esteem Scale is designed to assess global feelings of self-worth. The RSE includes 10 items (e.g. "I feel that I'm a person of worth'') rated on a four-point scale (1 = strongly disagree, 4 = strongly agree). A total score represents the sum of individual item responses. Scores range from 10 to 40 and higher scores indicate higher levels of self-esteem.

    Time frame: Postintervention assessments were conducted approximately 4 weeks following the baseline assessment.

  3. Rosenberg Self-Esteem Scale (RSE).

    The Rosenberg Self-Esteem Scale is designed to assess global feelings of self-worth. The RSE includes 10 items (e.g. "I feel that I'm a person of worth'') rated on a four-point scale (1 = strongly disagree, 4 = strongly agree). A total score represents the sum of individual item responses. Scores range from 10 to 40 and higher scores indicate higher levels of self-esteem.

    Time frame: Follow-up assessments began approximately 8 weeks after the postintervention assessment.

  4. Eating Disorder Examination Questionnaire (EDE-Q).

    The 28-item Eating Disorder Examination Questionnaire global score was used to measure eating disorder symptomatology. Participants report symptomatology over the past 28 days on a 7-point Likert scale from 0 (no days) to 6 (everyday). The EDE-Q contains 4 subscales: Restraint, Weight Concern, Eating Concern, and Shape Concern. Subscale scores are calculated by finding the averages of the subscale items. A global score is also calculated by averaging the subscale scores. Scores range from 0 to 6; higher scores indicate higher levels of eating disorder pathology.

    Time frame: Baseline assessments occurred after screening and prior to the delivery of any interventions.

  5. Eating Disorder Examination Questionnaire (EDE-Q).

    The 28-item Eating Disorder Examination Questionnaire global score was used to measure eating disorder symptomatology. Participants report symptomatology over the past 28 days on a 7-point Likert scale from 0 (no days) to 6 (everyday). The EDE-Q contains 4 subscales: Restraint, Weight Concern, Eating Concern, and Shape Concern. Subscale scores are calculated by finding the averages of the subscale items. A global score is also calculated by averaging the subscale scores. Scores range from 0 to 6; higher scores indicate higher levels of eating disorder pathology.

    Time frame: Postintervention assessments were conducted approximately 4 weeks following the baseline assessment.

  6. Eating Disorder Examination Questionnaire (EDE-Q).

    The 28-item Eating Disorder Examination Questionnaire global score was used to measure eating disorder symptomatology. Participants report symptomatology over the past 28 days on a 7-point Likert scale from 0 (no days) to 6 (everyday). The EDE-Q contains 4 subscales: Restraint, Weight Concern, Eating Concern, and Shape Concern. Subscale scores are calculated by finding the averages of the subscale items. A global score is also calculated by averaging the subscale scores. Scores range from 0 to 6; higher scores indicate higher levels of eating disorder pathology.

    Time frame: Follow-up assessments began approximately 8 weeks after the postintervention assessment.

  7. Body Shape Questionnaire (BSQ).

    The Body Shape Questionnaire (BSQ) was used to measure body dissatisfaction in the present trial. The BSQ is a 34-item scale. Items are measured on a 6-point Likert scale designed to assess the frequency of negative body-related thoughts (1= never, 6 = always). Individual items are summed to compute an overall score. Scores on this scale range from 34 to 204. Higher scores indicate higher frequency of negative body-related thoughts and higher levels of body dissatisfaction.

    Time frame: Baseline assessments occurred after screening and prior to the delivery of any interventions.

  8. Body Shape Questionnaire (BSQ).

    The Body Shape Questionnaire (BSQ) was used to measure body dissatisfaction in the present trial. The BSQ is a 34-item scale. Items are measured on a 6-point Likert scale designed to assess the frequency of negative body-related thoughts (1= never, 6 = always). Individual items are summed to compute an overall score. Scores on this scale range from 34 to 204. Higher scores indicate higher frequency of negative body-related thoughts and higher levels of body dissatisfaction.

    Time frame: Postintervention assessments were conducted approximately 4 weeks following the baseline assessment.

  9. Body Shape Questionnaire (BSQ).

    The Body Shape Questionnaire (BSQ) was used to measure body dissatisfaction in the present trial. The BSQ is a 34-item scale. Items are measured on a 6-point Likert scale designed to assess the frequency of negative body-related thoughts (1= never, 6 = always). Individual items are summed to compute an overall score. Scores on this scale range from 34 to 204. Higher scores indicate higher frequency of negative body-related thoughts and higher levels of body dissatisfaction.

    Time frame: Follow-up assessments began approximately 8 weeks after the postintervention assessment.

  10. Social Comparison Rating Scale (SCRS).

    The Social Comparison Rating Scale (SCRS) is an 11-item scale used to assess perception of social rank and social comparison tendencies in the present trial. The scale consists of a series of bipolar adjectives (e.g., inferior/superior) separated by the numbers 1 through 10. For each adjective pair, participants are asked to rank themselves in comparison to others. A score around 60 indicates a person, on average, sees themselves approximately equal to others. Higher scores indicate higher levels of favorable social comparison and higher perceived social rank.

    Time frame: Baseline assessments occurred after screening and prior to the delivery of any interventions.

  11. Social Comparison Rating Scale (SCRS).

    The Social Comparison Rating Scale (SCRS) is an 11-item scale used to assess perception of social rank and social comparison tendencies in the present trial. The scale consists of a series of bipolar adjectives (e.g., inferior/superior) separated by the numbers 1 through 10. For each adjective pair, participants are asked to rank themselves in comparison to others. A score around 60 indicates a person, on average, sees themselves approximately equal to others. Higher scores indicate higher levels of favorable social comparison and higher perceived social rank.

    Time frame: Postintervention assessments were conducted approximately 4 weeks following the baseline assessment.

  12. Social Comparison Rating Scale (SCRS).

    The Social Comparison Rating Scale (SCRS) is an 11-item scale used to assess perception of social rank and social comparison tendencies in the present trial. The scale consists of a series of bipolar adjectives (e.g., inferior/superior) separated by the numbers 1 through 10. For each adjective pair, participants are asked to rank themselves in comparison to others. A score around 60 indicates a person, on average, sees themselves approximately equal to others. Higher scores indicate higher levels of favorable social comparison and higher perceived social rank.

    Time frame: Follow-up assessments began approximately 8 weeks after the postintervention assessment.

  13. Self-Objectification Questionnaire (SOQ)

    The Self-Objectification Questionnaire (SOQ) is a 10-item self-report inventory designed to assess the relative importance of body competence versus body appearance in sense of self. Participants rank appearance- versus competence-based attributes from 0 to 9 with higher scores representing higher importance. An overall trait self-objectification score is computed by summing competence and appearance ratings and subtracting the sum of competence ratings from the sum of appearance ratings. Resulting scores range from -25 to 25. Higher scores denote higher levels of trait self-objectification.

    Time frame: Baseline assessments occurred after screening and prior to the delivery of any interventions.

  14. Self-Objectification Questionnaire (SOQ)

    The Self-Objectification Questionnaire (SOQ) is a 10-item self-report inventory designed to assess the relative importance of body competence versus body appearance in sense of self. Participants rank appearance- versus competence-based attributes from 0 to 9 with higher scores representing higher importance. An overall trait self-objectification score is computed by summing competence and appearance ratings and subtracting the sum of competence ratings from the sum of appearance ratings. Resulting scores range from -25 to 25. Higher scores denote higher levels of trait self-objectification.

    Time frame: Postintervention assessments were conducted approximately 4 weeks following the baseline assessment.

  15. Self-Objectification Questionnaire (SOQ)

    The Self-Objectification Questionnaire (SOQ) is a 10-item self-report inventory designed to assess the relative importance of body competence versus body appearance in sense of self. Participants rank appearance- versus competence-based attributes from 0 to 9 with higher scores representing higher importance. An overall trait self-objectification score is computed by summing competence and appearance ratings and subtracting the sum of competence ratings from the sum of appearance ratings. Resulting scores range from -25 to 25. Higher scores denote higher levels of trait self-objectification.

    Time frame: Follow-up assessments began approximately 8 weeks after the postintervention assessment.

  16. Ideal Body Stereotype Scale - Revised.

    The Ideal Body Stereotype Scale - Revised was used to assess the extent to which participants internalized the cultural feminine thin-ideal. The IBSS-R is a self-report inventory which asks participants to report their level of agreement with 6 statements which indicate what attractive women look like on a 5-point scale ranging from strongly disagree (1) to strongly agree (5). Responses are averaged to compute a total score. Scores ranges from 1 to 5; higher scores indicate higher levels of thin-ideal internalization.

    Time frame: Baseline assessments occurred after screening and prior to the delivery of any interventions.

  17. Ideal Body Stereotype Scale - Revised.

    The Ideal Body Stereotype Scale - Revised was used to assess the extent to which participants internalized the cultural feminine thin-ideal. The IBSS-R is a self-report inventory which asks participants to report their level of agreement with 6 statements which indicate what attractive women look like on a 5-point scale ranging from strongly disagree (1) to strongly agree (5). Responses are averaged to compute a total score. Scores ranges from 1 to 5; higher scores indicate higher levels of thin-ideal internalization.

    Time frame: Postintervention assessments were conducted approximately 4 weeks following the baseline assessment.

  18. Ideal Body Stereotype Scale - Revised.

    The Ideal Body Stereotype Scale - Revised was used to assess the extent to which participants internalized the cultural feminine thin-ideal. The IBSS-R is a self-report inventory which asks participants to report their level of agreement with 6 statements which indicate what attractive women look like on a 5-point scale ranging from strongly disagree (1) to strongly agree (5). Responses are averaged to compute a total score. Scores ranges from 1 to 5; higher scores indicate higher levels of thin-ideal internalization.

    Time frame: Follow-up assessments began approximately 8 weeks after the postintervention assessment.

  19. State Trait Anxiety Inventory - Form Y.

    The State Trait Anxiety Inventory- Form Y (STAI) is a 20-item self-report measure used to assess level of trait anxiety in the present study. Each item consists of a statement which assesses feelings of anxiety or relaxation on a 4-point scale ranging from 1 (not at all) to 4 (very much so). Responses to individual items are summed to create an overall score. Scores range from 20 to 80. Higher scores indicate higher levels of anxiety.

    Time frame: Baseline assessments occurred after screening and prior to the delivery of any interventions.

  20. State Trait Anxiety Inventory - Form Y.

    The State Trait Anxiety Inventory- Form Y (STAI) is a 20-item self-report measure used to assess level of trait anxiety in the present study. Each item consists of a statement which assesses feelings of anxiety or relaxation on a 4-point scale ranging from 1 (not at all) to 4 (very much so). Responses to individual items are summed to create an overall score. Scores range from 20 to 80. Higher scores indicate higher levels of anxiety.

    Time frame: Postintervention assessments were conducted approximately 4 weeks following the baseline assessment.

  21. State Trait Anxiety Inventory - Form Y.

    The State Trait Anxiety Inventory- Form Y (STAI) is a 20-item self-report measure used to assess level of trait anxiety in the present study. Each item consists of a statement which assesses feelings of anxiety or relaxation on a 4-point scale ranging from 1 (not at all) to 4 (very much so). Responses to individual items are summed to create an overall score. Scores range from 20 to 80. Higher scores indicate higher levels of anxiety.

    Time frame: Follow-up assessments began approximately 8 weeks after the postintervention assessment.

  22. Positive and Negative Affect Scale - Positive Affect

    The Positive and Negative Affect Schedule is a 20-item self-report questionnaire that used to measure positive and negative affect. Items are rated on a 5-point scale ranging from 1 (very slightly) to 5 (extremely) which measures the extent to which the client has experienced that affect over the past week. The 10 positive and 10 negative items are summed separately to create a positive affect score and a negative affect score respectively. Each score ranges between 0 and 50 with higher scores indicating higher positive or negative affect.

    Time frame: Baseline assessments occurred after screening and prior to the delivery of any interventions.

  23. Positive and Negative Affect Scale - Positive Affect

    The Positive and Negative Affect Schedule is a 20-item self-report questionnaire that used to measure positive and negative affect. Items are rated on a 5-point scale ranging from 1 (very slightly) to 5 (extremely) which measures the extent to which the client has experienced that affect over the past week. The 10 positive and 10 negative items are summed separately to create a positive affect score and a negative affect score respectively. Each score ranges between 0 and 50 with higher scores indicating higher positive or negative affect.

    Time frame: Postintervention assessments were conducted approximately 4 weeks following the baseline assessment.

  24. Positive and Negative Affect Scale - Positive Affect

    The Positive and Negative Affect Schedule is a 20-item self-report questionnaire that used to measure positive and negative affect. Items are rated on a 5-point scale ranging from 1 (very slightly) to 5 (extremely) which measures the extent to which the client has experienced that affect over the past week. The 10 positive and 10 negative items are summed separately to create a positive affect score and a negative affect score respectively. Each score ranges between 0 and 50 with higher scores indicating higher positive or negative affect.

    Time frame: Follow-up assessments began approximately 8 weeks after the postintervention assessment.

  25. Mean R Wave Amplitude

    Mean R wave amplitude was determined via a 3-lead ECG and was measured in millivolts (mV). The ECG signal was acquired via PowerLab 16/35 psychophysiological data acquisition system with a sampling rate of 1000 Hz. Hardware setup included an ECG100C amplifier with a 35Hz LPN filter and a .5Hz HP filter. ECG data were analyzed via PowerLab LabChart 8 software. A total of 5 minutes and 30 seconds of ECG data were collected to allow for artifact trimming. Artifacts were flagged by experimenters during data collection. Mean R wave amplitude represents ventricular depolarization. Higher magnitudes indicated increased polarity associated with an increased force of ventricular contraction.

    Time frame: Baseline assessments occurred after screening and prior to the delivery of any interventions.

  26. Mean R Wave Amplitude

    Mean R wave amplitude was determined via a 3-lead ECG and was measured in millivolts (mV). The ECG signal was acquired via PowerLab 16/35 psychophysiological data acquisition system with a sampling rate of 1000 Hz. Hardware setup included an ECG100C amplifier with a 35Hz LPN filter and a .5Hz HP filter. ECG data were analyzed via PowerLab LabChart 8 software. A total of 5 minutes and 30 seconds of ECG data were collected to allow for artifact trimming. Artifacts were flagged by experimenters during data collection. Mean R wave amplitude represents ventricular depolarization and is measured in millivolts. Higher magnitudes indicated increased polarity associated with an increased force of ventricular contraction.

    Time frame: Postintervention assessments were conducted approximately 4 weeks following the baseline assessment.

  27. Mean R Wave Amplitude

    Mean R wave amplitude was determined via a 3-lead ECG and was measured in millivolts (mV). The ECG signal was acquired via PowerLab 16/35 psychophysiological data acquisition system with a sampling rate of 1000 Hz. Hardware setup included an ECG100C amplifier with a 35Hz LPN filter and a .5Hz HP filter. ECG data were analyzed via PowerLab LabChart 8 software. A total of 5 minutes and 30 seconds of ECG data were collected to allow for artifact trimming. Artifacts were flagged by experimenters during data collection. Mean R wave amplitude represents ventricular depolarization and is measured in millivolts. Higher magnitudes indicated increased polarity associated with an increased force of ventricular contraction.

    Time frame: Follow-up assessments began approximately 8 weeks after the postintervention assessment.

  28. QT Interval Length

    QTc prolongation was measured in msec and was assessed via 3-lead ECG. The ECG signal was acquired via PowerLab 16/35 psychophysiological data acquisition system with a sampling rate of 1000 Hz. Hardware setup included an ECG100C amplifier with a 35Hz LPN filter and a .5Hz HP filter. ECG data were analyzed via PowerLab LabChart 8 software. For detection, typical QRS width was set at 80ms and R waves were at least 300ms apart. QTc was corrected with Bazett's formula. QT interval length represents the length of ventricular depolarization and repolarization and is measured in msec.

    Time frame: Baseline assessments occurred after screening and prior to the delivery of any interventions.

  29. QT Interval Length

    QTc prolongation was measured in msec and was assessed via 3-lead ECG. The ECG signal was acquired via PowerLab 16/35 psychophysiological data acquisition system with a sampling rate of 1000 Hz. Hardware setup included an ECG100C amplifier with a 35Hz LPN filter and a .5Hz HP filter. ECG data were analyzed via PowerLab LabChart 8 software. For detection, typical QRS width was set at 80ms and R waves were at least 300ms apart. QTc was corrected with Bazett's formula. QT interval length represents the length of ventricular depolarization and repolarization and is measured in msec.

    Time frame: Postintervention assessments were conducted approximately 4 weeks following the baseline assessment.

  30. QT Interval Length

    Mean scores and standard deviations were reported as a function of group and time. Single mean imputation was used to impute all missing scores to reflect a sample size of n=60 per condition (N=180 total) based on participants admitted at the beginning of the trial. The outcome analyses were based on imputed values and therefore, overall number of participants analyzed equals 60 per condition in the outcome analyses.

    Time frame: Follow-up assessments began approximately 8 weeks after the postintervention assessment.

  31. Vagal Cardiac Tone - High Frequency Spectral Power

    High frequency spectral power was assessed via heart rate variability (HRV) power spectral analysis of 3-lead ECG data and was reported in normalized units. The ECG signal was acquired via PowerLab 16/35 psychophysiological data acquisition system with a sampling rate of 1000 Hz. Hardware setup included an ECG100C amplifier with a 35Hz LPN filter and a .5Hz HP filter. ECG data were analyzed via PowerLab LabChart 8 software. Maximum frequency was set at 0.5 Hz with number of frequencies at 500. LF spectral power ranged from 0.04-0.15 Hz. HF spectral power ranged from 0.15-0.45 Hz. Increased high frequency spectral power represents increased vagal input to the heart.

    Time frame: Baseline assessments occurred after screening and prior to the delivery of any interventions.

  32. Vagal Cardiac Tone - High Frequency Spectral Power

    High frequency spectral power was assessed via heart rate variability (HRV) power spectral analysis of 3-lead ECG data and was reported in normalized units. The ECG signal was acquired via PowerLab 16/35 psychophysiological data acquisition system with a sampling rate of 1000 Hz. Hardware setup included an ECG100C amplifier with a 35Hz LPN filter and a .5Hz HP filter. ECG data were analyzed via PowerLab LabChart 8 software. Maximum frequency was set at 0.5 Hz with number of frequencies at 500. LF spectral power ranged from 0.04-0.15 Hz. HF spectral power ranged from 0.15-0.45 Hz. Increased high frequency spectral power represents increased vagal input to the heart.

    Time frame: Postintervention assessments were conducted approximately 4 weeks following the baseline assessment.

  33. Vagal Cardiac Tone - High Frequency Spectral Power

    High frequency spectral power was assessed via heart rate variability (HRV) power spectral analysis of 3-lead ECG data and was reported in normalized units. The ECG signal was acquired via PowerLab 16/35 psychophysiological data acquisition system with a sampling rate of 1000 Hz. Hardware setup included an ECG100C amplifier with a 35Hz LPN filter and a .5Hz HP filter. ECG data were analyzed via PowerLab LabChart 8 software. Maximum frequency was set at 0.5 Hz with number of frequencies at 500. LF spectral power ranged from 0.04-0.15 Hz. HF spectral power ranged from 0.15-0.45 Hz. Increased high frequency spectral power represents increased vagal input to the heart.

    Time frame: Follow-up assessments began approximately 8 weeks after the postintervention assessment.

  34. Sympathetic Cardiac Tone - Low Frequency High Frequency Spectral Power Ratio

    Low frequency to high frequency spectral power was assessed via heart rate variability (HRV) power spectral analysis of 3-lead ECG. This index was reported in normalized units. The ECG signal was acquired via PowerLab 16/35 psychophysiological data acquisition system with a sampling rate of 1000 Hz. Hardware setup included an ECG100C amplifier with a 35Hz LPN filter and a .5Hz HP filter. Maximum frequency was set at 0.5 Hz with number of frequencies at 500. LF spectral power ranged from 0.04-0.15 Hz. HF spectral power ranged from 0.15-0.45 Hz. The ratio is designed to assess degree of sympathetic innervation to the heart.

    Time frame: Baseline assessments occurred after screening and prior to the delivery of any interventions.

  35. Sympathetic Cardiac Tone - Low Frequency High Frequency Spectral Power Ratio

    Low frequency to high frequency spectral power was assessed via heart rate variability (HRV) power spectral analysis of 3-lead ECG. This index was reported in normalized units. The ECG signal was acquired via PowerLab 16/35 psychophysiological data acquisition system with a sampling rate of 1000 Hz. Hardware setup included an ECG100C amplifier with a 35Hz LPN filter and a .5Hz HP filter. Maximum frequency was set at 0.5 Hz with number of frequencies at 500. LF spectral power ranged from 0.04-0.15 Hz. HF spectral power ranged from 0.15-0.45 Hz. The ratio is designed to assess degree of sympathetic innervation to the heart.

    Time frame: Postintervention assessments were conducted approximately 4 weeks following the baseline assessment.

  36. Sympathetic Cardiac Tone - Low Frequency High Frequency Spectral Power Ratio

    Low frequency to high frequency spectral power was assessed via heart rate variability (HRV) power spectral analysis of 3-lead ECG. This index was reported in normalized units. The ECG signal was acquired via PowerLab 16/35 psychophysiological data acquisition system with a sampling rate of 1000 Hz. Hardware setup included an ECG100C amplifier with a 35Hz LPN filter and a .5Hz HP filter. Maximum frequency was set at 0.5 Hz with number of frequencies at 500. LF spectral power ranged from 0.04-0.15 Hz. HF spectral power ranged from 0.15-0.45 Hz. The ratio is designed to assess degree of sympathetic innervation to the heart.

    Time frame: Follow-up assessments began approximately 8 weeks after the postintervention assessment.

  37. Positive and Negative Affect Scale - Negative Affect

    The Positive and Negative Affect Schedule is a 20-item self-report questionnaire that used to measure positive and negative affect. Items are rated on a 5-point scale ranging from 1 (very slightly) to 5 (extremely) which measures the extent to which the client has experienced that affect over the past week. The 10 positive and 10 negative items are summed separately to create a positive affect score and a negative affect score respectively. Each score ranges between 0 and 50 with higher scores indicating higher positive or negative affect.

    Time frame: Baseline assessments occurred after screening and prior to the delivery of any interventions.

  38. Positive and Negative Affect Scale - Negative Affect

    The Positive and Negative Affect Schedule is a 20-item self-report questionnaire that used to measure positive and negative affect. Items are rated on a 5-point scale ranging from 1 (very slightly) to 5 (extremely) which measures the extent to which the client has experienced that affect over the past week. The 10 positive and 10 negative items are summed separately to create a positive affect score and a negative affect score respectively. Each score ranges between 0 and 50 with higher scores indicating higher positive or negative affect.

    Time frame: Postintervention assessments were conducted approximately 4 weeks following the baseline assessment.

  39. Positive and Negative Affect Scale - Negative Affect

    The Positive and Negative Affect Schedule is a 20-item self-report questionnaire that used to measure positive and negative affect. Items are rated on a 5-point scale ranging from 1 (very slightly) to 5 (extremely) which measures the extent to which the client has experienced that affect over the past week. The 10 positive and 10 negative items are summed separately to create a positive affect score and a negative affect score respectively. Each score ranges between 0 and 50 with higher scores indicating higher positive or negative affect.

    Time frame: Follow-up assessments began approximately 8 weeks after the postintervention assessment.

07

Results

Posted Dec 9, 2022

Participant flow

Women aged 15-35 displaying subclinical and clinical eating disorder symptoms were recruited from 2 Midwestern cities and 5 surrounding suburban communities from November of 2018 to March of 2021. All participants were treated in accordance with federal guidelines (Title 45, Code of Regulations Part 46) for the treatment of human participants. The research was approved by an Institutional Review Board at the host institution.

Participant flow — Overall Study
MilestoneEducational BrochureBody Project TraditionalBody Project Expanded
Started606060
Completed403845
Not completed202215

Outcome measures

PrimaryRosenberg Self-Esteem Scale (RSE).

The Rosenberg Self-Esteem Scale is designed to assess global feelings of self-worth. The RSE includes 10 items (e.g. "I feel that I'm a person of worth'') rated on a four-point scale (1 = strongly disagree, 4 = strongly agree). A total score represents the sum of individual item responses. Scores range from 10 to 40 and higher scores indicate higher levels of self-esteem.

Time frame:
Baseline assessments occurred after screening and prior to the delivery of any interventions.
Reported as:
Mean · units on a scale
Rosenberg Self-Esteem Scale (RSE).
units on a scaleEducational BrochureBody Project TraditionalBody Project Expanded
Rosenberg Self-Esteem Scale (RSE).22.71 ± 4.7122.50 ± 4.8122.62 ± 4.07
PrimaryRosenberg Self-Esteem Scale (RSE).

The Rosenberg Self-Esteem Scale is designed to assess global feelings of self-worth. The RSE includes 10 items (e.g. "I feel that I'm a person of worth'') rated on a four-point scale (1 = strongly disagree, 4 = strongly agree). A total score represents the sum of individual item responses. Scores range from 10 to 40 and higher scores indicate higher levels of self-esteem.

Time frame:
Postintervention assessments were conducted approximately 4 weeks following the baseline assessment.
Reported as:
Mean · units on a scale
Rosenberg Self-Esteem Scale (RSE).
units on a scaleEducational BrochureBody Project TraditionalBody Project Expanded
Rosenberg Self-Esteem Scale (RSE).23.55 ± 4.3025.45 ± 4.5025.08 ± 4.57
PrimaryRosenberg Self-Esteem Scale (RSE).

The Rosenberg Self-Esteem Scale is designed to assess global feelings of self-worth. The RSE includes 10 items (e.g. "I feel that I'm a person of worth'') rated on a four-point scale (1 = strongly disagree, 4 = strongly agree). A total score represents the sum of individual item responses. Scores range from 10 to 40 and higher scores indicate higher levels of self-esteem.

Time frame:
Follow-up assessments began approximately 8 weeks after the postintervention assessment.
Reported as:
Mean · units on a scale
Rosenberg Self-Esteem Scale (RSE).
units on a scaleEducational BrochureBody Project TraditionalBody Project Expanded
Rosenberg Self-Esteem Scale (RSE).24.55 ± 4.7425.55 ± 4.0926.60 ± 4.48
PrimaryEating Disorder Examination Questionnaire (EDE-Q).

The 28-item Eating Disorder Examination Questionnaire global score was used to measure eating disorder symptomatology. Participants report symptomatology over the past 28 days on a 7-point Likert scale from 0 (no days) to 6 (everyday). The EDE-Q contains 4 subscales: Restraint, Weight Concern, Eating Concern, and Shape Concern. Subscale scores are calculated by finding the averages of the subscale items. A global score is also calculated by averaging the subscale scores. Scores range from 0 to 6; higher scores indicate higher levels of eating disorder pathology.

Time frame:
Baseline assessments occurred after screening and prior to the delivery of any interventions.
Reported as:
Mean · units on a scale
Eating Disorder Examination Questionnaire (EDE-Q).
units on a scaleEducational BrochureBody Project TraditionalBody Project Expanded
Eating Disorder Examination Questionnaire (EDE-Q).4.25 ± .83.93 ± 1.153.96 ± 1.02
PrimaryEating Disorder Examination Questionnaire (EDE-Q).

The 28-item Eating Disorder Examination Questionnaire global score was used to measure eating disorder symptomatology. Participants report symptomatology over the past 28 days on a 7-point Likert scale from 0 (no days) to 6 (everyday). The EDE-Q contains 4 subscales: Restraint, Weight Concern, Eating Concern, and Shape Concern. Subscale scores are calculated by finding the averages of the subscale items. A global score is also calculated by averaging the subscale scores. Scores range from 0 to 6; higher scores indicate higher levels of eating disorder pathology.

Time frame:
Postintervention assessments were conducted approximately 4 weeks following the baseline assessment.
Reported as:
Mean · units on a scale
Eating Disorder Examination Questionnaire (EDE-Q).
units on a scaleEducational BrochureBody Project TraditionalBody Project Expanded
Eating Disorder Examination Questionnaire (EDE-Q).4.17 ± .642.93 ± 1.203.07 ± 1.23
PrimaryEating Disorder Examination Questionnaire (EDE-Q).

The 28-item Eating Disorder Examination Questionnaire global score was used to measure eating disorder symptomatology. Participants report symptomatology over the past 28 days on a 7-point Likert scale from 0 (no days) to 6 (everyday). The EDE-Q contains 4 subscales: Restraint, Weight Concern, Eating Concern, and Shape Concern. Subscale scores are calculated by finding the averages of the subscale items. A global score is also calculated by averaging the subscale scores. Scores range from 0 to 6; higher scores indicate higher levels of eating disorder pathology.

Time frame:
Follow-up assessments began approximately 8 weeks after the postintervention assessment.
Reported as:
Mean · units on a scale
Eating Disorder Examination Questionnaire (EDE-Q).
units on a scaleEducational BrochureBody Project TraditionalBody Project Expanded
Eating Disorder Examination Questionnaire (EDE-Q).3.74 ± .892.73 ± 1.202.78 ± 1.14
PrimaryBody Shape Questionnaire (BSQ).

The Body Shape Questionnaire (BSQ) was used to measure body dissatisfaction in the present trial. The BSQ is a 34-item scale. Items are measured on a 6-point Likert scale designed to assess the frequency of negative body-related thoughts (1= never, 6 = always). Individual items are summed to compute an overall score. Scores on this scale range from 34 to 204. Higher scores indicate higher frequency of negative body-related thoughts and higher levels of body dissatisfaction.

Time frame:
Baseline assessments occurred after screening and prior to the delivery of any interventions.
Reported as:
Mean · units on a scale
Body Shape Questionnaire (BSQ).
units on a scaleEducational BrochureBody Project TraditionalBody Project Expanded
Body Shape Questionnaire (BSQ).139.42 ± 23.92134.37 ± 30.15134.73 ± 28.32
PrimaryBody Shape Questionnaire (BSQ).

The Body Shape Questionnaire (BSQ) was used to measure body dissatisfaction in the present trial. The BSQ is a 34-item scale. Items are measured on a 6-point Likert scale designed to assess the frequency of negative body-related thoughts (1= never, 6 = always). Individual items are summed to compute an overall score. Scores on this scale range from 34 to 204. Higher scores indicate higher frequency of negative body-related thoughts and higher levels of body dissatisfaction.

Time frame:
Postintervention assessments were conducted approximately 4 weeks following the baseline assessment.
Reported as:
Mean · units on a scale
Body Shape Questionnaire (BSQ).
units on a scaleEducational BrochureBody Project TraditionalBody Project Expanded
Body Shape Questionnaire (BSQ).137.65 ± 20.91110.96 ± 33.39114.50 ± 30.96
PrimaryBody Shape Questionnaire (BSQ).

The Body Shape Questionnaire (BSQ) was used to measure body dissatisfaction in the present trial. The BSQ is a 34-item scale. Items are measured on a 6-point Likert scale designed to assess the frequency of negative body-related thoughts (1= never, 6 = always). Individual items are summed to compute an overall score. Scores on this scale range from 34 to 204. Higher scores indicate higher frequency of negative body-related thoughts and higher levels of body dissatisfaction.

Time frame:
Follow-up assessments began approximately 8 weeks after the postintervention assessment.
Reported as:
Mean · units on a scale
Body Shape Questionnaire (BSQ).
units on a scaleEducational BrochureBody Project TraditionalBody Project Expanded
Body Shape Questionnaire (BSQ).129.51 ± 23.74105.19 ± 32.23105.29 ± 28.28
PrimarySocial Comparison Rating Scale (SCRS).

The Social Comparison Rating Scale (SCRS) is an 11-item scale used to assess perception of social rank and social comparison tendencies in the present trial. The scale consists of a series of bipolar adjectives (e.g., inferior/superior) separated by the numbers 1 through 10. For each adjective pair, participants are asked to rank themselves in comparison to others. A score around 60 indicates a person, on average, sees themselves approximately equal to others. Higher scores indicate higher levels of favorable social comparison and higher perceived social rank.

Time frame:
Baseline assessments occurred after screening and prior to the delivery of any interventions.
Reported as:
Mean · units on a scale
Social Comparison Rating Scale (SCRS).
units on a scaleEducational BrochureBody Project TraditionalBody Project Expanded
Social Comparison Rating Scale (SCRS).45.59 ± 17.1043.83 ± 13.1843.00 ± 13.80
PrimarySocial Comparison Rating Scale (SCRS).

The Social Comparison Rating Scale (SCRS) is an 11-item scale used to assess perception of social rank and social comparison tendencies in the present trial. The scale consists of a series of bipolar adjectives (e.g., inferior/superior) separated by the numbers 1 through 10. For each adjective pair, participants are asked to rank themselves in comparison to others. A score around 60 indicates a person, on average, sees themselves approximately equal to others. Higher scores indicate higher levels of favorable social comparison and higher perceived social rank.

Time frame:
Postintervention assessments were conducted approximately 4 weeks following the baseline assessment.
Reported as:
Mean · units on a scale
Social Comparison Rating Scale (SCRS).
units on a scaleEducational BrochureBody Project TraditionalBody Project Expanded
Social Comparison Rating Scale (SCRS).51.02 ± 16.3451.09 ± 11.6847.35 ± 14.82
PrimarySocial Comparison Rating Scale (SCRS).

The Social Comparison Rating Scale (SCRS) is an 11-item scale used to assess perception of social rank and social comparison tendencies in the present trial. The scale consists of a series of bipolar adjectives (e.g., inferior/superior) separated by the numbers 1 through 10. For each adjective pair, participants are asked to rank themselves in comparison to others. A score around 60 indicates a person, on average, sees themselves approximately equal to others. Higher scores indicate higher levels of favorable social comparison and higher perceived social rank.

Time frame:
Follow-up assessments began approximately 8 weeks after the postintervention assessment.
Reported as:
Mean · units on a scale
Social Comparison Rating Scale (SCRS).
units on a scaleEducational BrochureBody Project TraditionalBody Project Expanded
Social Comparison Rating Scale (SCRS).46.28 ± 17.3953.39 ± 10.9353.18 ± 15.88
PrimarySelf-Objectification Questionnaire (SOQ)

The Self-Objectification Questionnaire (SOQ) is a 10-item self-report inventory designed to assess the relative importance of body competence versus body appearance in sense of self. Participants rank appearance- versus competence-based attributes from 0 to 9 with higher scores representing higher importance. An overall trait self-objectification score is computed by summing competence and appearance ratings and subtracting the sum of competence ratings from the sum of appearance ratings. Resulting scores range from -25 to 25. Higher scores denote higher levels of trait self-objectification.

Time frame:
Baseline assessments occurred after screening and prior to the delivery of any interventions.
Reported as:
Mean · units on a scale
Self-Objectification Questionnaire (SOQ)
units on a scaleEducational BrochureBody Project TraditionalBody Project Expanded
Self-Objectification Questionnaire (SOQ)10.13 ± 9.757.71 ± 13.116.32 ± 12.46
PrimarySelf-Objectification Questionnaire (SOQ)

The Self-Objectification Questionnaire (SOQ) is a 10-item self-report inventory designed to assess the relative importance of body competence versus body appearance in sense of self. Participants rank appearance- versus competence-based attributes from 0 to 9 with higher scores representing higher importance. An overall trait self-objectification score is computed by summing competence and appearance ratings and subtracting the sum of competence ratings from the sum of appearance ratings. Resulting scores range from -25 to 25. Higher scores denote higher levels of trait self-objectification.

Time frame:
Postintervention assessments were conducted approximately 4 weeks following the baseline assessment.
Reported as:
Mean · units on a scale
Self-Objectification Questionnaire (SOQ)
units on a scaleEducational BrochureBody Project TraditionalBody Project Expanded
Self-Objectification Questionnaire (SOQ)10.40 ± 9.086.70 ± 11.392.35 ± 13.65
PrimarySelf-Objectification Questionnaire (SOQ)

The Self-Objectification Questionnaire (SOQ) is a 10-item self-report inventory designed to assess the relative importance of body competence versus body appearance in sense of self. Participants rank appearance- versus competence-based attributes from 0 to 9 with higher scores representing higher importance. An overall trait self-objectification score is computed by summing competence and appearance ratings and subtracting the sum of competence ratings from the sum of appearance ratings. Resulting scores range from -25 to 25. Higher scores denote higher levels of trait self-objectification.

Time frame:
Follow-up assessments began approximately 8 weeks after the postintervention assessment.
Reported as:
Mean · units on a scale
Self-Objectification Questionnaire (SOQ)
units on a scaleEducational BrochureBody Project TraditionalBody Project Expanded
Self-Objectification Questionnaire (SOQ)9.80 ± 8.342.81 ± 12.391.78 ± 12.61
PrimaryIdeal Body Stereotype Scale - Revised.

The Ideal Body Stereotype Scale - Revised was used to assess the extent to which participants internalized the cultural feminine thin-ideal. The IBSS-R is a self-report inventory which asks participants to report their level of agreement with 6 statements which indicate what attractive women look like on a 5-point scale ranging from strongly disagree (1) to strongly agree (5). Responses are averaged to compute a total score. Scores ranges from 1 to 5; higher scores indicate higher levels of thin-ideal internalization.

Time frame:
Baseline assessments occurred after screening and prior to the delivery of any interventions.
Reported as:
Mean · units on a scale
Ideal Body Stereotype Scale - Revised.
units on a scaleEducational BrochureBody Project TraditionalBody Project Expanded
Ideal Body Stereotype Scale - Revised.3.81 ± 0.53.82 ± .453.76 ± .5
PrimaryIdeal Body Stereotype Scale - Revised.

The Ideal Body Stereotype Scale - Revised was used to assess the extent to which participants internalized the cultural feminine thin-ideal. The IBSS-R is a self-report inventory which asks participants to report their level of agreement with 6 statements which indicate what attractive women look like on a 5-point scale ranging from strongly disagree (1) to strongly agree (5). Responses are averaged to compute a total score. Scores ranges from 1 to 5; higher scores indicate higher levels of thin-ideal internalization.

Time frame:
Postintervention assessments were conducted approximately 4 weeks following the baseline assessment.
Reported as:
Mean · units on a scale
Ideal Body Stereotype Scale - Revised.
units on a scaleEducational BrochureBody Project TraditionalBody Project Expanded
Ideal Body Stereotype Scale - Revised.3.76 ± 0.473.39 ± .693.60 ± .54
PrimaryIdeal Body Stereotype Scale - Revised.

The Ideal Body Stereotype Scale - Revised was used to assess the extent to which participants internalized the cultural feminine thin-ideal. The IBSS-R is a self-report inventory which asks participants to report their level of agreement with 6 statements which indicate what attractive women look like on a 5-point scale ranging from strongly disagree (1) to strongly agree (5). Responses are averaged to compute a total score. Scores ranges from 1 to 5; higher scores indicate higher levels of thin-ideal internalization.

Time frame:
Follow-up assessments began approximately 8 weeks after the postintervention assessment.
Reported as:
Mean · units on a scale
Ideal Body Stereotype Scale - Revised.
units on a scaleEducational BrochureBody Project TraditionalBody Project Expanded
Ideal Body Stereotype Scale - Revised.3.76 ± .523.34 ± .593.46 ± .40
PrimaryState Trait Anxiety Inventory - Form Y.

The State Trait Anxiety Inventory- Form Y (STAI) is a 20-item self-report measure used to assess level of trait anxiety in the present study. Each item consists of a statement which assesses feelings of anxiety or relaxation on a 4-point scale ranging from 1 (not at all) to 4 (very much so). Responses to individual items are summed to create an overall score. Scores range from 20 to 80. Higher scores indicate higher levels of anxiety.

Time frame:
Baseline assessments occurred after screening and prior to the delivery of any interventions.
Reported as:
Mean · units on a scale
State Trait Anxiety Inventory - Form Y.
units on a scaleEducational BrochureBody Project TraditionalBody Project Expanded
State Trait Anxiety Inventory - Form Y.58.87 ± 8.4258.02 ± 7.8458.70 ± 7.90
PrimaryState Trait Anxiety Inventory - Form Y.

The State Trait Anxiety Inventory- Form Y (STAI) is a 20-item self-report measure used to assess level of trait anxiety in the present study. Each item consists of a statement which assesses feelings of anxiety or relaxation on a 4-point scale ranging from 1 (not at all) to 4 (very much so). Responses to individual items are summed to create an overall score. Scores range from 20 to 80. Higher scores indicate higher levels of anxiety.

Time frame:
Postintervention assessments were conducted approximately 4 weeks following the baseline assessment.
Reported as:
Mean · units on a scale
State Trait Anxiety Inventory - Form Y.
units on a scaleEducational BrochureBody Project TraditionalBody Project Expanded
State Trait Anxiety Inventory - Form Y.57.15 ± 7.3953.05 ± 8.2254.63 ± 9.31
PrimaryState Trait Anxiety Inventory - Form Y.

The State Trait Anxiety Inventory- Form Y (STAI) is a 20-item self-report measure used to assess level of trait anxiety in the present study. Each item consists of a statement which assesses feelings of anxiety or relaxation on a 4-point scale ranging from 1 (not at all) to 4 (very much so). Responses to individual items are summed to create an overall score. Scores range from 20 to 80. Higher scores indicate higher levels of anxiety.

Time frame:
Follow-up assessments began approximately 8 weeks after the postintervention assessment.
Reported as:
Mean · units on a scale
State Trait Anxiety Inventory - Form Y.
units on a scaleEducational BrochureBody Project TraditionalBody Project Expanded
State Trait Anxiety Inventory - Form Y.55.63 ± 9.4551.63 ± 7.0052.58 ± 9.71
PrimaryPositive and Negative Affect Scale - Positive Affect

The Positive and Negative Affect Schedule is a 20-item self-report questionnaire that used to measure positive and negative affect. Items are rated on a 5-point scale ranging from 1 (very slightly) to 5 (extremely) which measures the extent to which the client has experienced that affect over the past week. The 10 positive and 10 negative items are summed separately to create a positive affect score and a negative affect score respectively. Each score ranges between 0 and 50 with higher scores indicating higher positive or negative affect.

Time frame:
Baseline assessments occurred after screening and prior to the delivery of any interventions.
Reported as:
Mean · units on a scale
Positive and Negative Affect Scale - Positive Affect
units on a scaleEducational BrochureBody Project TraditionalBody Project Expanded
Positive and Negative Affect Scale - Positive Affect26.35 ± 5.7625.53 ± 7.1025.24 ± 6.46
PrimaryPositive and Negative Affect Scale - Positive Affect

The Positive and Negative Affect Schedule is a 20-item self-report questionnaire that used to measure positive and negative affect. Items are rated on a 5-point scale ranging from 1 (very slightly) to 5 (extremely) which measures the extent to which the client has experienced that affect over the past week. The 10 positive and 10 negative items are summed separately to create a positive affect score and a negative affect score respectively. Each score ranges between 0 and 50 with higher scores indicating higher positive or negative affect.

Time frame:
Postintervention assessments were conducted approximately 4 weeks following the baseline assessment.
Reported as:
Mean · units on a scale
Positive and Negative Affect Scale - Positive Affect
units on a scaleEducational BrochureBody Project TraditionalBody Project Expanded
Positive and Negative Affect Scale - Positive Affect25.54 ± 6.3628.57 ± 5.6427.82 ± 6.69
PrimaryPositive and Negative Affect Scale - Positive Affect

The Positive and Negative Affect Schedule is a 20-item self-report questionnaire that used to measure positive and negative affect. Items are rated on a 5-point scale ranging from 1 (very slightly) to 5 (extremely) which measures the extent to which the client has experienced that affect over the past week. The 10 positive and 10 negative items are summed separately to create a positive affect score and a negative affect score respectively. Each score ranges between 0 and 50 with higher scores indicating higher positive or negative affect.

Time frame:
Follow-up assessments began approximately 8 weeks after the postintervention assessment.
Reported as:
Mean · units on a scale
Positive and Negative Affect Scale - Positive Affect
units on a scaleEducational BrochureBody Project TraditionalBody Project Expanded
Positive and Negative Affect Scale - Positive Affect26.60 ± 6.4427.84 ± 5.8527.98 ± 5.26
PrimaryMean R Wave Amplitude

Mean R wave amplitude was determined via a 3-lead ECG and was measured in millivolts (mV). The ECG signal was acquired via PowerLab 16/35 psychophysiological data acquisition system with a sampling rate of 1000 Hz. Hardware setup included an ECG100C amplifier with a 35Hz LPN filter and a .5Hz HP filter. ECG data were analyzed via PowerLab LabChart 8 software. A total of 5 minutes and 30 seconds of ECG data were collected to allow for artifact trimming. Artifacts were flagged by experimenters during data collection. Mean R wave amplitude represents ventricular depolarization. Higher magnitudes indicated increased polarity associated with an increased force of ventricular contraction.

Time frame:
Baseline assessments occurred after screening and prior to the delivery of any interventions.
Reported as:
Mean · millivolts (mV)
Mean R Wave Amplitude
millivolts (mV)Educational BrochureBody Project TraditionalBody Project Expanded
Mean R Wave Amplitude1.27 ± .361.19 ± .311.27 ± .36
PrimaryMean R Wave Amplitude

Mean R wave amplitude was determined via a 3-lead ECG and was measured in millivolts (mV). The ECG signal was acquired via PowerLab 16/35 psychophysiological data acquisition system with a sampling rate of 1000 Hz. Hardware setup included an ECG100C amplifier with a 35Hz LPN filter and a .5Hz HP filter. ECG data were analyzed via PowerLab LabChart 8 software. A total of 5 minutes and 30 seconds of ECG data were collected to allow for artifact trimming. Artifacts were flagged by experimenters during data collection. Mean R wave amplitude represents ventricular depolarization and is measured in millivolts. Higher magnitudes indicated increased polarity associated with an increased force of ventricular contraction.

Time frame:
Postintervention assessments were conducted approximately 4 weeks following the baseline assessment.
Reported as:
Mean · millivolts (mV)
Mean R Wave Amplitude
millivolts (mV)Educational BrochureBody Project TraditionalBody Project Expanded
Mean R Wave Amplitude1.32 ± .321.19 ± .241.27 ± .36
PrimaryMean R Wave Amplitude

Mean R wave amplitude was determined via a 3-lead ECG and was measured in millivolts (mV). The ECG signal was acquired via PowerLab 16/35 psychophysiological data acquisition system with a sampling rate of 1000 Hz. Hardware setup included an ECG100C amplifier with a 35Hz LPN filter and a .5Hz HP filter. ECG data were analyzed via PowerLab LabChart 8 software. A total of 5 minutes and 30 seconds of ECG data were collected to allow for artifact trimming. Artifacts were flagged by experimenters during data collection. Mean R wave amplitude represents ventricular depolarization and is measured in millivolts. Higher magnitudes indicated increased polarity associated with an increased force of ventricular contraction.

Time frame:
Follow-up assessments began approximately 8 weeks after the postintervention assessment.
Reported as:
Mean · millivolts (mV)
Mean R Wave Amplitude
millivolts (mV)Educational BrochureBody Project TraditionalBody Project Expanded
Mean R Wave Amplitude1.26 ± .311.14 ± .261.12 ± .26
PrimaryQT Interval Length

QTc prolongation was measured in msec and was assessed via 3-lead ECG. The ECG signal was acquired via PowerLab 16/35 psychophysiological data acquisition system with a sampling rate of 1000 Hz. Hardware setup included an ECG100C amplifier with a 35Hz LPN filter and a .5Hz HP filter. ECG data were analyzed via PowerLab LabChart 8 software. For detection, typical QRS width was set at 80ms and R waves were at least 300ms apart. QTc was corrected with Bazett's formula. QT interval length represents the length of ventricular depolarization and repolarization and is measured in msec.

Time frame:
Baseline assessments occurred after screening and prior to the delivery of any interventions.
Reported as:
Mean · msec
QT Interval Length
msecEducational BrochureBody Project TraditionalBody Project Expanded
QT Interval Length.38 ± .02.38 ± .02.38 ± .02
PrimaryQT Interval Length

QTc prolongation was measured in msec and was assessed via 3-lead ECG. The ECG signal was acquired via PowerLab 16/35 psychophysiological data acquisition system with a sampling rate of 1000 Hz. Hardware setup included an ECG100C amplifier with a 35Hz LPN filter and a .5Hz HP filter. ECG data were analyzed via PowerLab LabChart 8 software. For detection, typical QRS width was set at 80ms and R waves were at least 300ms apart. QTc was corrected with Bazett's formula. QT interval length represents the length of ventricular depolarization and repolarization and is measured in msec.

Time frame:
Postintervention assessments were conducted approximately 4 weeks following the baseline assessment.
Reported as:
Mean · msec
QT Interval Length
msecEducational BrochureBody Project TraditionalBody Project Expanded
QT Interval Length.38 ± .02.39 ± .01.39 ± .01
PrimaryQT Interval Length

Mean scores and standard deviations were reported as a function of group and time. Single mean imputation was used to impute all missing scores to reflect a sample size of n=60 per condition (N=180 total) based on participants admitted at the beginning of the trial. The outcome analyses were based on imputed values and therefore, overall number of participants analyzed equals 60 per condition in the outcome analyses.

Time frame:
Follow-up assessments began approximately 8 weeks after the postintervention assessment.
Reported as:
Mean · msec
QT Interval Length
msecEducational BrochureBody Project TraditionalBody Project Expanded
QT Interval Length.38 ± .02.38 ± .01.38 ± .01
PrimaryVagal Cardiac Tone - High Frequency Spectral Power

High frequency spectral power was assessed via heart rate variability (HRV) power spectral analysis of 3-lead ECG data and was reported in normalized units. The ECG signal was acquired via PowerLab 16/35 psychophysiological data acquisition system with a sampling rate of 1000 Hz. Hardware setup included an ECG100C amplifier with a 35Hz LPN filter and a .5Hz HP filter. ECG data were analyzed via PowerLab LabChart 8 software. Maximum frequency was set at 0.5 Hz with number of frequencies at 500. LF spectral power ranged from 0.04-0.15 Hz. HF spectral power ranged from 0.15-0.45 Hz. Increased high frequency spectral power represents increased vagal input to the heart.

Time frame:
Baseline assessments occurred after screening and prior to the delivery of any interventions.
Reported as:
Mean · Normalized units: HF (watts/Hz)
Vagal Cardiac Tone - High Frequency Spectral Power
Normalized units: HF (watts/Hz)Educational BrochureBody Project TraditionalBody Project Expanded
Vagal Cardiac Tone - High Frequency Spectral Power60.08 ± 19.5657.26 ± 19.7861.61 ± 5.87
PrimaryVagal Cardiac Tone - High Frequency Spectral Power

High frequency spectral power was assessed via heart rate variability (HRV) power spectral analysis of 3-lead ECG data and was reported in normalized units. The ECG signal was acquired via PowerLab 16/35 psychophysiological data acquisition system with a sampling rate of 1000 Hz. Hardware setup included an ECG100C amplifier with a 35Hz LPN filter and a .5Hz HP filter. ECG data were analyzed via PowerLab LabChart 8 software. Maximum frequency was set at 0.5 Hz with number of frequencies at 500. LF spectral power ranged from 0.04-0.15 Hz. HF spectral power ranged from 0.15-0.45 Hz. Increased high frequency spectral power represents increased vagal input to the heart.

Time frame:
Postintervention assessments were conducted approximately 4 weeks following the baseline assessment.
Reported as:
Mean · Normalized units: HF (watts/Hz)
Vagal Cardiac Tone - High Frequency Spectral Power
Normalized units: HF (watts/Hz)Educational BrochureBody Project TraditionalBody Project Expanded
Vagal Cardiac Tone - High Frequency Spectral Power60.15 ± 21.2060.04 ± 23.4660.58 ± 17.52
PrimaryVagal Cardiac Tone - High Frequency Spectral Power

High frequency spectral power was assessed via heart rate variability (HRV) power spectral analysis of 3-lead ECG data and was reported in normalized units. The ECG signal was acquired via PowerLab 16/35 psychophysiological data acquisition system with a sampling rate of 1000 Hz. Hardware setup included an ECG100C amplifier with a 35Hz LPN filter and a .5Hz HP filter. ECG data were analyzed via PowerLab LabChart 8 software. Maximum frequency was set at 0.5 Hz with number of frequencies at 500. LF spectral power ranged from 0.04-0.15 Hz. HF spectral power ranged from 0.15-0.45 Hz. Increased high frequency spectral power represents increased vagal input to the heart.

Time frame:
Follow-up assessments began approximately 8 weeks after the postintervention assessment.
Reported as:
Mean · Normalized units: HF (watts/Hz)
Vagal Cardiac Tone - High Frequency Spectral Power
Normalized units: HF (watts/Hz)Educational BrochureBody Project TraditionalBody Project Expanded
Vagal Cardiac Tone - High Frequency Spectral Power51.65 ± 20.5656.60 ± 22.8358.81 ± 19.68
PrimarySympathetic Cardiac Tone - Low Frequency High Frequency Spectral Power Ratio

Low frequency to high frequency spectral power was assessed via heart rate variability (HRV) power spectral analysis of 3-lead ECG. This index was reported in normalized units. The ECG signal was acquired via PowerLab 16/35 psychophysiological data acquisition system with a sampling rate of 1000 Hz. Hardware setup included an ECG100C amplifier with a 35Hz LPN filter and a .5Hz HP filter. Maximum frequency was set at 0.5 Hz with number of frequencies at 500. LF spectral power ranged from 0.04-0.15 Hz. HF spectral power ranged from 0.15-0.45 Hz. The ratio is designed to assess degree of sympathetic innervation to the heart.

Time frame:
Baseline assessments occurred after screening and prior to the delivery of any interventions.
Reported as:
Mean · ratio: LF (watts/HZ) / HF (watts/Hz)
Sympathetic Cardiac Tone - Low Frequency High Frequency Spectral Power Ratio
ratio: LF (watts/HZ) / HF (watts/Hz)Educational BrochureBody Project TraditionalBody Project Expanded
Sympathetic Cardiac Tone - Low Frequency High Frequency Spectral Power Ratio1.02 ± 1.55.99 ± .84.72 ± .53
PrimarySympathetic Cardiac Tone - Low Frequency High Frequency Spectral Power Ratio

Low frequency to high frequency spectral power was assessed via heart rate variability (HRV) power spectral analysis of 3-lead ECG. This index was reported in normalized units. The ECG signal was acquired via PowerLab 16/35 psychophysiological data acquisition system with a sampling rate of 1000 Hz. Hardware setup included an ECG100C amplifier with a 35Hz LPN filter and a .5Hz HP filter. Maximum frequency was set at 0.5 Hz with number of frequencies at 500. LF spectral power ranged from 0.04-0.15 Hz. HF spectral power ranged from 0.15-0.45 Hz. The ratio is designed to assess degree of sympathetic innervation to the heart.

Time frame:
Postintervention assessments were conducted approximately 4 weeks following the baseline assessment.
Reported as:
Mean · ratio: LF (watts/HZ) / HF (watts/Hz)
Sympathetic Cardiac Tone - Low Frequency High Frequency Spectral Power Ratio
ratio: LF (watts/HZ) / HF (watts/Hz)Educational BrochureBody Project TraditionalBody Project Expanded
Sympathetic Cardiac Tone - Low Frequency High Frequency Spectral Power Ratio1.45 ± 3.511.05 ± 1.17.85 ± 1.02
PrimarySympathetic Cardiac Tone - Low Frequency High Frequency Spectral Power Ratio

Low frequency to high frequency spectral power was assessed via heart rate variability (HRV) power spectral analysis of 3-lead ECG. This index was reported in normalized units. The ECG signal was acquired via PowerLab 16/35 psychophysiological data acquisition system with a sampling rate of 1000 Hz. Hardware setup included an ECG100C amplifier with a 35Hz LPN filter and a .5Hz HP filter. Maximum frequency was set at 0.5 Hz with number of frequencies at 500. LF spectral power ranged from 0.04-0.15 Hz. HF spectral power ranged from 0.15-0.45 Hz. The ratio is designed to assess degree of sympathetic innervation to the heart.

Time frame:
Follow-up assessments began approximately 8 weeks after the postintervention assessment.
Reported as:
Mean · ratio: LF (watts/HZ) / HF (watts/Hz)
Sympathetic Cardiac Tone - Low Frequency High Frequency Spectral Power Ratio
ratio: LF (watts/HZ) / HF (watts/Hz)Educational BrochureBody Project TraditionalBody Project Expanded
Sympathetic Cardiac Tone - Low Frequency High Frequency Spectral Power Ratio1.54 ± 1.991.86 ± 4.641.32 ± 2.84
PrimaryPositive and Negative Affect Scale - Negative Affect

The Positive and Negative Affect Schedule is a 20-item self-report questionnaire that used to measure positive and negative affect. Items are rated on a 5-point scale ranging from 1 (very slightly) to 5 (extremely) which measures the extent to which the client has experienced that affect over the past week. The 10 positive and 10 negative items are summed separately to create a positive affect score and a negative affect score respectively. Each score ranges between 0 and 50 with higher scores indicating higher positive or negative affect.

Time frame:
Baseline assessments occurred after screening and prior to the delivery of any interventions.
Reported as:
Mean · units on a scale
Positive and Negative Affect Scale - Negative Affect
units on a scaleEducational BrochureBody Project TraditionalBody Project Expanded
Positive and Negative Affect Scale - Negative Affect30.15 ± 7.4629.00 ± 6.8829.64 ± 6.60
PrimaryPositive and Negative Affect Scale - Negative Affect

The Positive and Negative Affect Schedule is a 20-item self-report questionnaire that used to measure positive and negative affect. Items are rated on a 5-point scale ranging from 1 (very slightly) to 5 (extremely) which measures the extent to which the client has experienced that affect over the past week. The 10 positive and 10 negative items are summed separately to create a positive affect score and a negative affect score respectively. Each score ranges between 0 and 50 with higher scores indicating higher positive or negative affect.

Time frame:
Postintervention assessments were conducted approximately 4 weeks following the baseline assessment.
Reported as:
Mean · units on a scale
Positive and Negative Affect Scale - Negative Affect
units on a scaleEducational BrochureBody Project TraditionalBody Project Expanded
Positive and Negative Affect Scale - Negative Affect29.63 ± 6.6725.61 ± 6.9925.59 ± 6.89
PrimaryPositive and Negative Affect Scale - Negative Affect

The Positive and Negative Affect Schedule is a 20-item self-report questionnaire that used to measure positive and negative affect. Items are rated on a 5-point scale ranging from 1 (very slightly) to 5 (extremely) which measures the extent to which the client has experienced that affect over the past week. The 10 positive and 10 negative items are summed separately to create a positive affect score and a negative affect score respectively. Each score ranges between 0 and 50 with higher scores indicating higher positive or negative affect.

Time frame:
Follow-up assessments began approximately 8 weeks after the postintervention assessment.
Reported as:
Mean · units on a scale
Positive and Negative Affect Scale - Negative Affect
units on a scaleEducational BrochureBody Project TraditionalBody Project Expanded
Positive and Negative Affect Scale - Negative Affect28.50 ± 7.9624.24 ± 6.2425.00 ± 5.82

Adverse events

Collected over Information regarding adverse events were reported at baseline, postintervention (approximately 4 weeks after treatment initiation) and 2-month follow-up (approximately 8 weeks after treatment conclusion).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Educational Brochure0/60 (0%)1/60 (1.7%)0/60 (0%)
Body Project Traditional0/60 (0%)0/60 (0%)0/60 (0%)
Body Project Expanded0/60 (0%)2/60 (3.3%)0/60 (0%)
Most frequent serious events
Most frequent serious events
EventEducational BrochureBody Project TraditionalBody Project Expanded
Suicidal IdeationPsychiatric disorders0/600/602/60
HospitalizationPsychiatric disorders1/600/600/60

Baseline characteristics

The numbers presented in the Baseline Analysis Population indicate the number of participants as a function of condition who completed the baseline assessment session. This differs from the number of participants in the Participant Flow Module because that module reflects the number of participants who completed the pre-trial screening and were enrolled in the trial. The discrepancy is explained by participants not attending the baseline assessment following study enrollment at screening.

Age, Continuous
Age, Continuous(years)Educational BrochureBody Project TraditionalBody Project ExpandedTotal
Mean22.48 ± 3.6323.95 ± 5.7321.73 ± 4.0822.75 ± 4.65
Sex: Female, Male
Sex: Female, Male(Participants)Educational BrochureBody Project TraditionalBody Project ExpandedTotal
Female495150150
Male0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Educational BrochureBody Project TraditionalBody Project ExpandedTotal
American Indian or Alaska Native0112
Asian0213
Native Hawaiian or Other Pacific Islander0000
Black or African American22610
White424238122
More than one race4318
Unknown or Not Reported1135
Region of Enrollment
Region of Enrollment(Participants)Educational BrochureBody Project TraditionalBody Project ExpandedTotal
United States495150150
Rosenberg Self-Esteem Scale
Rosenberg Self-Esteem Scale(units on a scale)Educational BrochureBody Project TraditionalBody Project ExpandedTotal
Mean22.71 ± 4.7122.50 ± 4.8122.62 ± 4.0722.61 ± 4.53
Eating Disorder Examination Questionnaire
Eating Disorder Examination Questionnaire(units on a scale)Educational BrochureBody Project TraditionalBody Project ExpandedTotal
Mean4.25 ± 0.83.93 ± 1.153.96 ± 1.024.04 ± 1.00
Body Shape Questionnaire
Body Shape Questionnaire(units on a scale)Educational BrochureBody Project TraditionalBody Project ExpandedTotal
Mean139.42 ± 23.92134.37 ± 30.15134.73 ± 28.32136.17 ± 27.55
Social Comparison Rating Scale
Social Comparison Rating Scale(units on a scale)Educational BrochureBody Project TraditionalBody Project ExpandedTotal
Mean45.59 ± 17.1043.83 ± 13.1843.00 ± 13.8044.15 ± 14.75

9 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Cornell College Eating Disorder Institute
    Mount Vernon, Iowa 52314, United States
09

References and documents

Study documents

  • Study protocol · May 8, 2018
  • Statistical analysis plan · May 8, 2018
  • Informed consent form · Dec 8, 2018

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — Data will be made available to other researchers upon request and subject to signed confidentiality agreement.

Supporting information: Study protocol, Sap, Icf, Csr, Analytic code

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03796091
Lead sponsor
Cornell College
Collaborators
National Institute of Mental Health (NIMH)
Responsible party
Dr. Melinda Green (Principal Investigator, Cornell College) — Principal investigator
First posted
Jan 8, 2019
Start date
Nov 18, 2018
Primary completion
Apr 15, 2021
Completion
Apr 15, 2021
Results posted
Dec 9, 2022
Last update
Dec 9, 2022

Study contacts

Melinda A Green, PhD
principal investigator · Green Counseling Services PLLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion